News & AnalysisAIDS Research

FDA Panel Recommends Anti-HIV Drug for Prevention

Science  18 May 2012:
Vol. 336, Issue 6083, pp. 792
DOI: 10.1126/science.336.6083.792

You are currently viewing the summary.

View Full Text

Summary

On 10 May, the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) held a marathon debate about whether an anti-HIV drug on the market as a treatment should receive approval as a preventive for uninfected people. For more than 12 hours, the committee heard scientific evidence and impassioned arguments for and against, ultimately recommending that FDA approve the use of the drug Truvada for what's called pre-exposure prophylaxis (PrEP). The decision was not unanimous, and there was a protracted back and forth about how to reduce the possibility that PrEP might cause more harm than good.